Pharma Focus Asia
KP - Choose our fully recyclable blister films

Lemonex's mRNA-DegradaBALL Vaccine (LEM-mR203) IND Application Approved for Phase 1 Clinical Trial

Thursday, August 10, 2023

Lemonex announced the approval of an Investigational New Drug (IND) application by the Ministry of Food and Drug Safety (MFDS) for revolutionary mRNA vaccine candidate, LEM-mR203, which incorporates their pioneering nano-drug delivery technology, DegradaBALL®.

The scope of this clinical trial encompasses the evaluation of safety and immunogenicity in healthy adults with a specific focus on addressing the ongoing Covid-19 pandemic. Distinguished by its unique attribute, LEM-mR203 is the first mRNA vaccine candidate to integrate the proprietary drug delivery platform technology, DegradaBALL-mRNA system. 

The current lipid nanoparticle (LNP) technology used in existing mRNA vaccines has problems related to allergic reactions or heart issues like myocarditis. The newly developed DegradaBALL drug delivery technology holds promise in mitigating these concerns, suggesting advancement for mRNA vaccines and therapeutics.

The mRNA vaccines offer an accelerated response due to their rapid development cycle compared to antigen protein vaccines. Nevertheless, the efficacy of mRNA delivery within the body hinges on proficient drug delivery technology.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayMerck - Mobius® productsThermo Fisher Scientific - Peptones5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024